ICU · SeaStar Medical Holding Corp
Substantial doubt about the company's ability to continue as a going concern.
“The Company believes that these conditions raise substantial doubt about its ability to continue as a going concern.”View the 10-Q filed Aug 12, 2026
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| $1.71M | $1.23M | $135K | $0 | — | — | |
| $126K | $53K | $0 | $0 | — | — | |
| $1.59M | $1.18M | $135K | $0 | — | — | |
| — | 95.71% | 100% | — | — | — | |
| $8.91M | $7.52M | $9.11M | $5.97M | $2.5M | $2.77M | |
| $6.66M | $5.84M | $8.87M | $8.24M | $6.92M | $1.68M | |
| $15.58M | $13.36M | $17.98M | $14.21M | $11.61M | $4.45M | |
| -$13.99M | -$12.18M | -$17.84M | -$14.21M | -$11.61M | -$4.45M | |
| — | -986.63% | -13216.3% | — | — | — | |
| $25K | $31K | $244K | $1.08M | $630K | $212K | |
| $392K | $325K | $101K | $0 | — | $11.82K | |
| $367K | $28K | -$6.99M | -$12.02M | -$580K | -$148K | |
| -$13.62M | -$12.15M | -$24.83M | -$26.23M | -$12.19M | -$4.6M | |
| $3000 | $3000 | $3000 | $0 | $1000 | -$1000 | |
| -$13.63M | -$12.15M | -$24.83M | -$26.23M | -$12.19M | -$4.6M | |
| — | -984.6% | -18392.59% | — | — | — | |
| USD/shares | — | -$5.86 | -$66.33 | -$302.60 | -$370.00 | -$157.50 |
| USD/shares | — | — | -$66.30 | -$302.60 | -$370.00 | -$157.50 |
| shares | — | 2.07M | 374.36K | 86.68K | 32.85K | 28.96K |
| shares | — | — | 374.36K | 86.68K | 32.85K | 28.96K |
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 222 similar-size Biotechnology companies (of 545 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | FY2025 | FY2024 |
|---|---|---|
| Pediatric Scds | $1,200,000 | $100,000 |